Fetal and Neonatal Effects of N-Acetylcysteine When Used for Neuroprotection in Maternal Chorioamnionitis

详细信息    查看全文

• 作者：Dorothea D. Jenkins ; MD¹ ; ^{jenkd@musc.edu" class="auth_mail" title="E-mail the corresponding author} ; Donald B. Wiest ; PharmD² ; Denise M. Mulvihill ; MD¹ ; Anthony M. Hlavacek ; MD¹ ; Sarah J. Majstoravich ; MD¹ ; Truman R. Brown ; PhD³ ; Joseph J. Taylor ; PhD³ ; ⁴ ; Jason R. Buckley ; MD¹ ; Robert P. Turner ; MD⁵ ; Laura Grace Rollins ; MS⁶ ; Jessica P. Bentzley ; BA¹ ; Kathryn E. Hope ; MPH¹ ; Andrew B. Barbour ; PhD¹ ; Danielle W. Lowe ; BS¹ ; Renee H. Martin ; PhD⁷ ; Eugene Y. Chang ; MD⁸
• 关键词：ACA ; Anterior cerebral artery ; AE ; Adverse event ; BA ; Basilar artery ; BG ; Basal ganglia ; BP ; Blood pressure ; CBF ; Cerebral blood flow ; CNS ; Central nervous system ; CSF ; Cerebrospinal fluid ; CUS ; Cranial ultrasound ; DIC ; Disseminated intravascular coagulopathy ; DOL ; Day of life ; EEG ; Electroencephalogram ; FIRS ; Fetal inflammatory state ; GA ; Gestational age ; HI ; Hypoxic ischemic ; HIE ; HI encephalopathy ; HOL ; Hour of life ; IL ; Interleukin ; IL-1Ra ; IL-1 receptor antagonist ; IVH ; Intraventricular hem
• 刊名：The Journal of Pediatrics
• 出版年：2016
• 出版时间：January 2016
• 年：2016
• 卷：168
• 期：Complete
• 页码：67-76.e6
• 全文大小：2270 K

文摘

To evaluate the clinical safety of antenatal and postnatal N-acetylcysteine (NAC) as a neuroprotective agent in maternal chorioamnionitis in a randomized, controlled, double-blinded trial.

Study design

Twenty-two mothers >24 weeks gestation presenting within 4 hours of diagnosis of clinical chorioamnionitis were randomized with their 24 infants to NAC or saline treatment. Antenatal NAC (100 mg/kg/dose) or saline was given intravenously every 6 hours until delivery. Postnatally, NAC (12.5-25 mg/kg/dose, n = 12) or saline (n = 12) was given every 12 hours for 5 doses. Doppler studies of fetal umbilical and fetal and infant cerebral blood flow, cranial ultrasounds, echocardiograms, cerebral oxygenation, electroencephalograms, and serum cytokines were evaluated before and after treatment, and 12, 24, and 48 hours after birth. Magnetic resonance spectroscopy and diffusion imaging were performed at term age equivalent. Development was followed for cerebral palsy or autism to 4 years of age.

Results

Cardiovascular measures, cerebral blood flow velocity and vascular resistance, and cerebral oxygenation did not differ between treatment groups. Cerebrovascular coupling was disrupted in infants with chorioamnionitis treated with saline but preserved in infants treated with NAC, suggesting improved vascular regulation in the presence of neuroinflammation. Infants treated with NAC had higher serum anti-inflammatory interleukin-1 receptor antagonist and lower proinflammatory vascular endothelial growth factor over time vs controls. No adverse events related to NAC administration were noted.

Conclusions

In this cohort of newborns exposed to chorioamnionitis, antenatal and postnatal NAC was safe, preserved cerebrovascular regulation, and increased an anti-inflammatory neuroprotective protein.

Trial registration

ClinicalTrials.gov: NCT00724594.